Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort
- 8 January 2021
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (12) , 1914-1923
Abstract
The objective of this study is to assess the association between vascular comorbidity burden with clinical and imaging features of disease burden in a large population of people with multiple sclerosis (MS). We included participants from the MS Partners Advancing Technology Health Solutions (MS PATHS) cohort. We evaluated if vascular comorbidities (diabetes, hypertension, and dyslipidemia) or a composite sum of comorbidities was associated with MS characteristics, including objective neurologic function assessments and quantitative brain magnetic resonance imaging (MRI) measurements in propensity score–weighted models. In total, 11,506 participants (6409 (55%) with brain MRI) were included. Individuals with 2+ vascular comorbidities had slower walking speed (standard deviation (SD) = −0.49; 95% confidence interval (CI) = −0.78, −0.19; p = 0.001), slower manual dexterity (SD = −0.41; 95% CI = −0.57, −0.26; p < 0.0001), and fewer correct scores on cognitive processing speed (SD = −0.11; 95% CI = −0.20, −0.02; p = 0.02) versus those with no comorbidities. Those with 2+ had lower brain parenchymal (−0.41%, 95% CI = −0.64, −0.17) and gray matter fractions (−0.30%, 95% CI = −0.49, −0.10), including reduced cortical (−10.10 mL, 95% CI = −15.42, −4.78) and deep (−0.44 mL, 95% CI = −0.84, −0.04) gray matter volumes versus those with no comorbidity. Increased vascular comorbidity burden was associated with clinical and imaging markers of neurologic dysfunction and neurodegeneration in MS. Strategies to optimize comorbidity management in people with MS are warranted.Keywords
This publication has 29 references indexed in Scilit:
- Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease courseMultiple Sclerosis Journal, 2016
- Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple SclerosisJAMA Neurology, 2016
- Recommendations for observational studies of comorbidity in multiple sclerosisNeurology, 2016
- Differing trends in the incidence of vascular comorbidity in MS and the general populationNeurology Clinical Practice, 2016
- Effect of comorbidity on mortality in multiple sclerosisNeurology, 2015
- An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer's diseaseNeuroImage: Clinical, 2015
- Brain Imaging Changes Associated With Risk Factors for Cardiovascular and Cerebrovascular Disease in Asymptomatic PatientsJACC: Cardiovascular Imaging, 2014
- Association of type 2 diabetes with brain atrophy and cognitive impairmentNeurology, 2014
- Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosisBMC Neurology, 2013
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009